Company intelligence / Profile preview

Elasmogen Ltd

Aberdeen, Scotland, United Kingdomelasmogen.com ↗

Ownership: Private
Development stage: Other

Overview

No clinical trial data published yet; pipeline assets are in late-stage pre-clinical development with promising first-in-class drug conjugates and bi-specific products. The lead oncology program partnered with Almac Discovery targets ROR1 using a soloMER-drug conjugate approach. The autoimmune portfolio includes novel orphan therapies for difficult-to-treat inflammatory eye diseases.

Therapeutic areas: OncologyImmunology
Modalities: Proprietary biologics called soloMERs™ derived from shark immune system molecules, which are antibody-like but smaller and more stable.
Industry: Biotech

Drug pipeline

1 asset

ELN28

Preclinical

Partnerships

Almac Discovery Ltd for oncology drug candidate developmentFeldan Therapeutics collaboration with Amgen to develop intracellular biologics combining Feldan Shuttle and Elasmogen’s soloMER technology

Beyond the preview

Go deeper on Elasmogen Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elasmogen Ltd.